Stockscreener 앱 받기
3.64
0.55%
-0.02
전일 마감가:
$3.66
열려 있는:
$3.6
하루 거래량:
18,140
Relative Volume:
0.28
시가총액:
$15.76M
수익:
$1.99M
순이익/손실:
$-5.28M
주가수익비율:
-2.6517
EPS:
-1.3727
순현금흐름:
$-3.59M
1주 성능:
-5.08%
1개월 성능:
+14.47%
6개월 성능:
+167.65%
1년 성능:
+20.53%
1일 변동 폭
$3.573
$3.67
1주일 범위
$3.55
$3.94
52주 변동 폭
$1.0266
$8.48
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
명칭
Cyclerion Therapeutics Inc
전화
617-621-7722
주소
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.64 | 15.85M | 1.99M | -5.28M | -3.59M | -1.3727 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-20 | 개시 | Truist | Buy |
| 2021-09-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 개시 | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal - Stock Titan
Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing - Stock Titan
EDGAR Filing Documents for 0001193125-26-301054 - SEC.gov
Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Price to sales forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN) - TradingView
Cyclerion Therapeutics (CYCN) Faces Resistance as Shares Slide Nearly 4%Put Support - dars.gov.et
Cyclerion Therapeutics (CYCN) Edges Higher as Stock Tests Key ResistanceTriple MA Cross - DonanımHaber
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics Inc (CYCN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cyclerion Therapeutics Inc (CYCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding - marketscreener.com
Cyclerion Therapeutics (CYCN) Hovers Near $3.00 as Low Volume Caps MovementDark Pool Volume - newsline.com
Cyclerion (NASDAQ: CYCN) to Merge with Korsana, $380M Pre-Closing Financing - Stock Titan
CYCN Q4 2025 Earnings: Narrowed Loss Surpasses Estimates Amid Pipeline ProgressEarnings Outlook Update - newsline.com
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion Therapeutics (CYCN) Edges Higher Amid Quiet TradingCash Flow Strong Stocks - The Legal Advocate
CYCN Q4 2025 Earnings: Narrowed Losses Exceed Expectations as Development Programs ProgressPre-Earnings Drift - The Legal Advocate
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
Cyclerion Therapeutics Company Profile & Introduction - Moomoo
CYCN - Finviz
Cyclerion Therapeutics (CYCN) Edges Higher as Shares Test Key Resistance LevelsRounding Bottom - The Legal Advocate
Cyclerion Shares to Watch With Deal in Focus as Markets Reopen - Bez Kabli
CYCN Q4 2025 Earnings: Narrowed Loss Beats Street Estimates, Shares ClimbAnnual Report - newsline.com
Cyclerion (CYCN) Delivers Q4 2025 Beat — EPS $-0.21 vs $-0.39 ExpectedTangible Book Value - newsline.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
TradingKey - TradingKey
CYCN News | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill
Why Cyclerion (CYCN) deserves a deeper look right now (-2.78%) 2026-05-07Insider Info - newser.com
FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G - Stock Titan
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? - Sahm
CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration By Investing.com - Investing.com Nigeria
Cyclerion Therapeutics 2024 10-K/A Amendment: Executive Compensation, Governance, and Equity Awards Overview - Minichart
Cyclerion Therapeutics (NASDAQ: CYCN) updates board, compensation and PIPE details - Stock Titan
CYCN stock is soaring 150% pre-market today — what is fueling the rally? - MSN
CYCN SEC FilingsCyclerion Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cyclerion Merges with Korsana to Develop Alzheimer Antibody Therapy - HarianBasis.co
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline - Insider Monkey
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Is Cyclerion (CYCN) stock outperforming similar companies (Drifts Higher) 2026-04-18Open Stock Signal Network - Xã Thanh Hà
EDGAR Filing Documents for 0001193125-26-162177 - SEC.gov
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Yahoo Finance
Published on: 2026-04-13 23:21:17 - baoquankhu1.vn
Cyclerion Therapeutics Inc (CYCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
2.11%
자본화:
|
볼륨(24시간):